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BACKGROUND:  
KIT and PDGFR mutations are central events in GIST pathogenesis. Target 
therapy activity depends on mutation setting. 
AIMS  OF THE THESIS 
A retrospective analysis of GIST cases followed in our center during the last 
decade to evaluate how the genetic alteration may influence the therapeutic 
decision and the prognosis of GIST patients.  
 
MATERIALS AND METHODS:In the 2000-2010 period, our Center followed 80 
localized or metastatic GIST patients, and 76 were followed with regular follow-
up. The mutational analysis for c-KIT and PDGFRα genes was realized for 54/80 
patients. RFS was stratifyng for risk under Fletcher and Miettinem 
classifications. The response to tyrosine kinase inhibitors treatment was 
evaluated by integrating the RECIST criteria with the new CHOI. PFS for each 
treatment was calculated. 
RESULTS: The median onset age was 55 years.  54 cases analyzed by primary 
genetic mutations had a frequency resulting as follows: 34 c-kitt 11, 8 c-kit 9, 1 
PDGFR 12, 4 PDGFR18, 7 WT. Relapse patients were 20; 13/20  showed c-KIT 
in exon 11 mutation, two in exon 9, one PDGFRα, two Wild Type. The RFS 
mediane in high risk patients was 31 months, in low/moderate risk was not 
reached within the five follow-up years (Fletcher classification p:0.17; 
Miettinem p:0.03). Three-years PFS with Imatinib 400mg/die on 19 patients 
shows a 27 months mediane. PFS in patients were: with Imatinib 800 mg/mq 9 
months, Sunitinib 4 months, Nilotinib 3 months. 
 
CONCLUSIONS: The data we obtained are in line with the literature data. 
Miettinen’s risk stratification proves to have better predictive value than 
Fletcher.Mutational statusofprimary tumorsis closelyrelatedto the 
effectivenessoftreatmentwithimatinibandothertyrosine kinasesinhibitors. The 
genetic analysis should be a standard of the diagnostic-staging iter of GIST 
patients. 
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Introduction 
Stromal Gastrointestinal Tumors (GIST) are rare; In Europe the annual incidence 
is 6.6-14.5 per million of inhabitants, which means 1-3% of all tumors. (1) 
Nevertheless GISTs are the most common mesenchimal tumors of 
gastrointestinal apparatus. (2) 
The tumor can occur at any age but most GIST patients are detected in their 6
th
 
or 7
th
 decades, while only 10% are below 40 year of age.  
99% of cases occur in a sporadic form, even though a small percentage of 
inheritable-familial GIST exist, frequently as multiple Gist  (Carney triade, 
neurofibromatosis). 
Only since the Nineties GIST were recognized and classified as a separate clinical 
and istological subtype from others mesenchimal tumors.  
GISTs can occur in every intestinal tract, sometimes also outside. These is their 
presentation rate: 
-Stomach: 40-70% 
-Small-bowel: 20-40% 
-Esophagus: 5% 
-Rectum: 5-15% 
-Omento-Mesentere: < 5% 
Their growth pattern is most commonly extramural; therefore, they rarely 
result in obstruction, but sometimes they occur with free intra-abdominal 
bleeding from central tumor necrosis and peritoneal breaking. As a result of 
their insidious nature and growth pattern, more than three-fourths of these 
tumors exceed 5 cm in diameter at time of diagnosis. 
GIST are frequently roundish friable and un-encapsulated masses. Biggest 
tumors can have a cystic degeneration, necrosis and haemorrhagic areas; they 
can break spontaneously or during surgery. Most GISTs are spindle cell tumors 
(70%), and a minority mixed splindle (10%), ephitelioid (20%), or rarely 
pleomorphic. 
GIST major characteristic is their peculiar immunohistochemical profile: 95% 
expresses c-Kit protein (CD117), tyrosine kinase transmembrane receptor. 
Approximately 80-75% of GISTs show a mutation in the Kit proto-oncogene.(3) 
About 10% of GISTs’ mutations are not identifiable, but Kit is nonetheless 
strongly activated. 
Data on PDGFR expression are scant, and many available antibodies are not 
reliable on paraffin-embedded tissue. However, some studies suggest that 
PDGFR can be a diagnostic immune-histochemical marker. 
Other commonly expressed but less GIST-specific antigens are: Protein Kinase 
theta, DOG1,CD34, SMA (4-5-6) 
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Table1differential kinds of diagnosis (7) 
 KIT CD34 SMA Desmina S100 
Indagini 
molecolari 
GIST + (95%) 
+ (70-
80%) 
+ focal 
(70%) 
+ focal 
(50%) 
+ 
focal 
(5%) 
KIT 
PDGFRα 
 
Leiomuscolar 
tumors 
- 
+ (10-
15%) 
+ 
diffused 
+ spread Rare  
Schwannoma - + - - +  
Fibromatosis debated Rare + 
Rare 
cells 
- 
Multiβ-
catenina 
Clear cell 
Sarcoma 
- - - - + 
EWS-ATB-
1 
EWS-CREB 
Sinovial 
Sarcoma  
- - - - - 
SYT-SSX1 
SYT-SSX2 
Melanoma + focal - - - + KIT 
 
KIT and PDGFR mutations are central events in sporadic GIST pathogenesis and 
their identification is becoming increasingly important, since specific treatments 
on oncogenic KIT and PDGFR activation (especially imatinib mesylate) have 
become available. KIT and PDGFRA genes are located pericentromerically at 
4q12, the corresponding proteins have structural characteristics of type III 
receptor tyrosine kinase family. Activating mutations permit the 
phosphorylation of the tyrosine kinases receptor, dimerization and the 
regulation of cell proliferation, apoptosis, chemotaxis and adhesion. 
Many patients experiencing Imatinib-induced remission develop metastases 
with acquired medicine resistance, usually based on secondary Imatinib-
resistant mutations in Kit and PDGFR tyrosine kinase domains. 
KIT mutations in GIST are clustered in four exons. They are, in decreasing order 
of frequency, exon 11, exon 9, exon 13 and exon 17. Most common are exon 11 
(juxtamembrane domain) mutations, including delection, point mutation and 
duplications. Older studies argue that mutations in exon 11 are related to a 
more aggressive disease, larger tumors, high mitotic index and worse outcome 
(8). 
Exon 9 mutations (5-10%) (extracellular domain) usually are 2-codon 502-503 
duplications and mostly occur in intestinal GISTs. Most small intestinal tumors 
with such mutation have been malignant, but it seems to be related to the 
worse prognosis of small intestinal GISTs in general. A lower Imatinib sensitivity 
of these tumors has been noticed. 
Exon 17 mutations (tyrosine kinase 2 domain) have been reported few times. 
GISTs with such mutations are variably sensitive to imatinib. 
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Three different regions of PDGFR have been found to be mutated in GISTs. They 
are, in decreasing order of frequency exon 18, exon 12 (juxtamembrane 
domain), and exon 14. The secondary point mutations are especially in exon 18. 
The exon 18 mutations are Imatinib-resistant; the missense mutations affecting 
exon 14 seem to be associated with low Kit expression and unexpectedly 
favorable prognosis. 
Thestudiesthatledto thesediscoveriesare notonlyanintellectual speculation; 
tumorlocation, itsbenign ormalignant grade and clinicalandpathologicfeatures 
are highly dependent on themutationalpattern(9). 
 
 
Table2 A summaryofcorrelationsbetweenhistopathologic 
featuresandmutation( 10-11-12-5). 
 
Gene Mutation Clinical implications Istotypes 
Prognostic 
value 
KIT   
Exon 9 
Ala502_Tyr503dup 
strongly correlated 
to intestinal  GIST 
(>90%) 
Frequently splidle 
cell tumors 
None 
prognostic 
value  
 
KIT   
Exon 11 
Deletions  
Insertions various 
gastrointestinal 
location 
many patterns of 
splindle cells  
probable 
malignant 
behavior 
Sostitutions 
Probable 
benign  
behavior 
PDGFRα 
Exon 18 
Deletion  
Sostitution 
strongly correlated 
to gastric  GIST 
(>95%) 
Frequently 
ephitelioid cell 
tumors 
Probable 
benign  
behavior 
KIT 
PDGFRα 
WT 
Wild Type 
various 
gastrointestinal 
location 
Splindle  and 
epitelioid cell 
tumors  None 
prognostic 
value  
 
GIST correlated to  
NF1 
splidle cell tumors 
Pediatric GIST 
correlated to Carney 
Syndrome 
ephitelioid cell 
tumors 
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In Table 3, sensitivity and responsiveness in vitro of different genotypes of KIT 
and PDGFRα to treatment with Imatinib.  
 
Gene Exon Mutatione Sensibility 
KIT 
9 Ala502_Tyr503dup 
RC 5% 
PR 29% 
SD 47% 
PD 17% 
11 
Deletion 
Sostitution 
Insertione 
RC 6% 
PR 61% 
SD 25% 
PD 3% 
PDGFRα 18 
Asp842_Met844del 
Ile843_His845del 
Asp842Val 
Some resistent mutations. RO in many 
cases  
KIT 
PDGFRα 
WT WT 
PR 23% 
SD 50% 
PD 19% 
 
There is no consent about a uniform staging method, and none of the current 
classifications is completely satisfying (Tabella 4). 
 
Table 4: AJCC 2002, from the NCCN 2008 guidelines (13) 
T1 o Tumor dimension: less than 5cm 
in his widest diameter. 
o T1a: Superficial tumor 
o T1b: Deep tumor 
T2 T2: Tumor dimension: more than 
5cm 
o T2a: Superficial tumor 
o T2b: Deep tumor 
N0       Absence of lymph nodal 
metastasis 
N1 Presence of lymph nodal 
metastasis 
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In 2001, National Institute of Health (NIH) organized an experts consensus 
where was discussed the metastasis risk stratification, based on the dimension 
of the tumor and mitotic count expressed as number of mitosis for 50 HPF 
(high-power field).  
 
Table 5 Relapse and metastasis risk stratification by NIH/Fletcher 
Dimension (cm) 
Mitotic index (#/50HPF) 
<5/50 HPF 5-10/50HPF >10/50HPF 
<2 Low Moderated high 
2-5 Low Moderated       high 
5-10 Moderated high       high 
>10 High high        high 
 
However, in 2006 AFIP (American Forces Institute of Pathology) anatomo-
pathologists, in the largest set of GIST in literature (1900 patients) observed 
that small intestine and rectal GIST have a greater malicious potential than 
stomach GIST. Therefore the tumor location is today a useful prognostic factor. 
Five risk classes are considered (none, very low, low, average, high). (2) 
 
M0 Absence of distance metastasis 
M1 Presence of distance metastasis 
G1 Well-differentiated tumor 
G2  Midly-differentiated tumor 
G3 - Slightly-differentiated tumor 
G4  Non-differentiated tumor 
Stage T N M G 
Stage I T1a, T1b, T2a, T2b N0 M0 G1, G2 
Stage II T1a, T1b, T2a N0 M0 G3, G4 
Stage III T2b N0 M0 G3, G4 
Stage IV Ogni T 
N1 M0 
Ogni G 
N0 M1 
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Picture 1 Free survival from disease based on dimension, mitosis and primitive 
tumor location. (14) 
 
Table 6 Relapse and metastasis risk stratification by Miettinen 
size and mitotic 
index 
Location 
Stomach Digiunum/Ileum Duodenum Rectum 
<5/50HPF 
<2 
cm 
None 0% None 0% None 0% 
None 
0% 
2-5 
cm 
Very  low 
1,9% 
low 4,3% low 8,3% 
low 
8,5% 
5-10 
cm 
low 3,6% Moderate 24% high 34% high 7% 
>10 
cm 
Moderate 
12% 
high 52% high 34% 
high 
57% 
>5/50HPF 
<2 
cm 
None high 50% N. D. 
high 
54% 
2-5 
cm 
Moderate 
16% 
high 73% high 50% 
high 
52% 
5-10 
cm 
high 55% high 85% high 86% 
high 
71% 
>10 
cm 
high 85% high 90% high 86% 
high 
71% 
 
The recent revision of 2008 classification suggests to consider as additional 
factors the tumor breaking and the hemoperitoneus, the mucosal invasion. R0 
surgery is a prognostic factor too and is still the preferred treatment as well as 
the only one that can ensure recovery. According to ESMO guidelines, when an 
R0 surgery can induce complication or appears to be complicated, an Imatinib 
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neo-adjuvant treatment may be foreseen, after a multi-zonal analysis in order 
to identify refractory tumors.  
Imatinib approval as GIST adjuvant therapy by FDA and EMEA, was based on a 
stage III randomized double-blind study, Imatinib vs. Placebo (ACOSOG Z9001) 
(15), which proved an advantage of Imatinib 400 mg/day for one year (97% vs 
83%) in terms of one-year relapse-free patients percentage. Randomization was 
stratified on tumor size (from 3 to <6 cm, from 6 to <10 cm, and10 cm). OS, 
secondary endpoint, did not prove to be modified during this period, however 
the follow-up period is short and distorted by the crossover, which was 
expected by the study. 
Two randomized studies (EORTC 62024, SSG XVIII/AIO) are currently ongoing, in 
order to understand how Imatinib affects OS in adjuvant setting and the 
possible advantage of a therapy extension from one to two years. 
 
 
 
Picture 2  Disease and global free survival in patients treated with Imatinib VS 
placebo. An improvement of free disease survival is not associated with a 
significant improvement of global survival.  
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Present recommendations from NCCN suggest the prescription of adjuvant 
Imatinib for at least 12 months (as by trial ACOSOG Z9001) in average/high-risk 
patients, with standard 400mg dosage. In62005 study, patients 
withexon9KITmutations,treatedwithimatinib800mg/die,hadsignificantlysuperior
PFSanda61% reduction in the relative riskthan patientstreatedwith 
400mg/day(16). 
 
 
Picture 3 Studio 62005. Progression free survival in different setting of 
mutations. 
 
In a study imatinib was able to inhibit all PDGFR mutations except the D842V 
(62.9 % ). This particular mutation’s resistance to imatinib restricts his use in 
about one third of GIST with PDGFR mutation.  
However, even after a complete surgical removal of primary GIST, at least 40% 
patients faces relapse within 5 years (17). 
The initial approval of Imatinib for advanced GIST treatment by FDA in 2002 is 
based on a study about 147 patients with non-resectable or metastatic GIST, in 
which 38% of patients show a partial response with a volumetric reduction 
bigger than 50% (18). After a number of clinic trials 55-80% of metastatic GIST 
patients obtains a partial response or a disease stabilization. Most common 
adverse reactions include oedema, rash, diarrhea, nausea, abdominal pain, 
fatigue. FDA and EMEA recommend to start the treatment in a metastatic 
patient with a single dose of 400mg/day. The augmentation of the dosage to 
800mg/day (double dose) may be chosen for patients with exon 9 of c-KIT gene 
mutation, or with evident signs of progression after the 400mg dose, (19).  It is 
a daily treatment, as it is known that its suspension, even if just for one day, 
may cause the re-ignition of the disease, which can be shown by PET (PET flare).  
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Table 7 Meta-GIST study (20) was presented at 2007 ASCO and clearly shows 
how the Imatinib response is strictly connected with the mutational condition: 
Mutation 
Status 
Median 
Progression- 
Free Survival 
(mesi) 
Percent 
3-year 
PFS 
Median 
Overall 
Survival 
(mesi) 
Percent 
3-year 
OS 
KIT exon 
11 
26 38% 60 69% 
KIT exon 9 13 11% 31 44% 
Wildtype 16 27% 43 57% 
Other 11 9% 34 46% 
 
Table 8 The same meta-analysis also confirmed the benefit from a 800mg 
Imatinib treatment in case of exon 9 mutation: 
Imatinib 
Dose 
Median Progression- 
Free Survival (mesi) 
Percent 
3-year PFS 
Median Overall 
Survival (mesi) 
Percent 
3-year OS 
400 mg 6 5% 28 37% 
800 mg 19 17% 35 49% 
 
In patients with disease progress, it is possible to increase Imatinib dose or to 
move to a second-line therapy with Sunitinib, a tyrosine kinase inhibitor. The 
supporting study for Sunitinib approval as second-line treatment for 
progressing or Imatinib-intolerant GIST is double-blind randomized VS placebo. 
Patients who received Sunitinib benefited from an increase of the Time To 
Progression of more than four times than placebo (27,3 weeks against 6,4 
weeks; HR 0,33, p<0,0001) (20). Although the clinical benefit is significant in all 
patterns, the primary response is significantly higher in exon 9-mutated tumors 
(21). 
Picture  
4 PFS and OS in Sunitinib patients VS Placebo National Comprehensive Cancer 
Network, 2008 
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Following studies proved that the minimum effective dose is 37,5mg/day and 
that the best treatment schedule is daily therapy without interruption – this, 
against a relatively low toxicity increase, leads to a clinic benefit as it avoids the 
rebound effect. Sunitinib toxicity includes hematological and coagulation 
alterations, thrombocytopenia, hand-foot syndrome, mucositis. 
There is no current indication about a third-line treatment, even if a lot of 
phase-III trials are in progress. The use of other second-generation tyrosine 
kinase inhibitors (Nilotinib, Dasatinib, Masitinib) is still under review by clinical 
testing. Nilotinib is a very well-tolerated medicine that has shown antitumor 
activity but dosen’t seem to show improved survival. (22) The inhibition of 
alternative targets, such as components of signal transduction downstream of 
KIT and PDGFRα, including AKT and mTOR, has been tested in vitro and in vivo 
(everolimus) (23). Even anti-angiogenesis show an antitumor activity in GIST. 
More recently, other strategies are based, for example, on heat-shock protein 
HSP-90 inhibition, a member of chaperone proteins that plays a peculiar role in 
the stabilization and protection from the degradation of c-KIT. (24).Although 
preclinical studies proved a remarkable antitumor activity, clinical tests have 
been early stopped because of the occurrence of toxicity deaths. Regorafenin, 
oral multi-kinase inhibitor developed which targets angiogenic, stromal and 
oncogenic receptor tyrosine kinase (RTK) is currently being studied in a 
randomized, placebo-controlled phase III study for metastatic and/or 
unresectable GIST, progressed despite prior treatment with at least imatinib 
and sunitinib.  
 
Tabella 9 
 
Farmaco Target molecolare 
Nilotinib KIT, PDGFRα, BCR-ABL 
AZD2171 VEGFR, KIT, PDGFRs 
Pkc412 KIT, PFGFRs, VEGFR-2, PKC 
AMG 706 VEGFR, KIT, PDGFRs, RET 
Everolimus mTOR 
Sorafenib RAF 
Regorafenib VEGFR2, TIE2 
 
NCCN guidelines, updated in 2008, recommend Best Supportive Care after a 
Sunitinib therapy fail. However, some studies encourage an Imatinib re-
challenge, at least in patients who showed good responses to the first-line 
therapy as it seems useful in decelerating the disease’s progression. 
The current WHO, SWOG and RECIST criteria (Response Evaluation Criteria in 
Solid Tumors) do not consider that GIST don’t often decrease their dimension, 
but show other types of responses such as tissue response (density reduction), 
because of necrosis, intra-tumor hemorrhage or fibromixoid degeneration. 
13 
 
Choi, comparing relation between the variation of the tumor dimension and CT 
density with the responses by 18FDG-PET, established new response criteria 
(reduction of tumor dimension ≥10% or a decrease of the tumor density (HU) 
≥15% at TC) (25-26-27) providing a better prognostic parameter in terms of Free 
Disease Survival than RECIST criteria. 
 
 
 
AIMS  OF THE THESIS 
The purpose of this study is the retrospective analysis of the cases that have 
been followed in our center during the last decade. In particular, we evaluated 
the possible biological and clinical relations in order to verify how the genetic 
alteration may influence the therapeutic decision and the prognosis of GIST 
patients.  
 
MATERIALS AND METHODS  
In the 2000-2010 Patients period, our Reference Center followed 80 localized or 
metastatic GIST patients, and 76 of these were followed with regular, therefore 
evaluable, follow-up.  
GIST diagnosis was placed on mesenchymal cancer CD117+ or CD117- with 
positive mutational analysis for alterations on c-KIT or PDGFRα. 
The anatomic-pathologic data provided, besides the evaluation of resection 
margins, the dimension of the tumor, the histological subtype and the number 
of mitosis. In relation to these data it was possible to locate each case in a 
specific risk class, based on the universally accepted risk classification 
NIH/Fletcher (Fletcher, Berman, & Corless, 2002). The cases were also 
evaluated according to the location and then classified under Miettinen 
(Miettinen & Lasota, 2006). 
The mutational analysis for c-KIT and PDGFRα genes was realized for 54/80 
patients. 
The instrumental analysis used in the disease staging, the evaluation of the 
therapeutic response to the treatment and in follow-up were CT, PET and NMR, 
CEUS for the morpho-functional evaluation of hepatic and peritoneal 
localizations. In gastric or rectal GIST cases, endoscopy and sometimes eco-
endoscopy were also used. 
Surgery was considered complete if the disease was “en bloc” resected at the 
initial exploration reporting negative surgical margins (R0). The presence of 
onset hemoperitoneum or tumor breaking was considered R1 surgery. 
The response to tyrosine kinase inhibitors treatment was evaluated by 
integrating the classic dimensional response criteria (RECIST) with the new ones 
(CHOI), that consider tissue modifications (biologic response), documented by 
radiological tests in terms of NMR signal intensity variation, density at CT and 
uptake (SUV) in case of PET. 
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Patients Sex Age  Stage Sites Size Mutation  Fletcher Risk 
1 M 49 Localized Stomach >10 cm c-kit 11 High 
2 F 77 Localized Small-bowel 5-10 cm  Intermedio 
3 F 60 Localized Small-bowel 5-10 cm  Intermedio 
4 M 39 Localized Stomach >10 cm c-kit 11 High 
5 F 46 Localized Stomach 2-5 cm  Low 
6 M 45 Localized Unknown >10 cm c-kit 11 High 
7 M 66 Localized Small-bowel >10 cm c-kit 11 High 
8 F 45 Localized Small-bowel 5-10 cm c-kit 11 High 
9 F 61 Localized Stomach 2-5 cm  Low 
10 M 67 Localized Stomah 5-10 cm c-kit 11 Intermedio 
11 F 62 Localized Small-bowel >10 cm c-kit 11 Intermedio 
12 F 49 Metastatic Peritoneo  c-kit 9  
13 M 40 Metastatic Rectum  
PDGFRα 
18  
14 M 62 Localized Stomach 5-10 cm 
PDGFRα 
18 Intermedio 
15 F 64 Localized Stomach 2-5 cm  Low 
16 M 43 Localized Small-bowel 5-10 cm c-kit 9 Intermedio 
17 M 57 Localized Stomach <2 cm c-kit 11 very low 
18 F 44 Localized Small-bowel 2-5 cm  Low 
19 F 52 Localized Small-bowel 5-10 cm c-kit 11 High 
20 F 63 Localized Small-bowel 2-5 cm WT Low 
21 M 45 Metastatic Esophagus  c-kit 11  
22 M 71 Localized Rectum 2-5 cm c-kit 11 Low 
23 M 54 Localized Stomach 5-10 cm c-kit 11 Intermedio 
24 M 75 Localized Stomach 2-5 cm  Low 
25 M 25 Localized Stomach >10 cm c-kit 11 High 
26 M 60 Localized Stomach 2-5 cm WT Low 
27 M 50 Localized Stomach >10 cm WT High 
28 F 62 Localized Small-bowel >10 cm c-kit 11 High 
29 F 44 Localized Stomach 5-10 cm WT Intermedio 
30 M 56 Localized Stomach 5-10 cm c-kit 11 Intermedio 
31 F 81 Metastatic Stomach  c-kit 11  
32 M 40 Localized Stomach 5-10 cm  Intermedio 
33 F 49 Localized Small-bowel 5-10 cm c-kit 9 Intermedio 
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34 M 53 Localized Small-bowel 2-5 cm  Low 
35 M 71 Localized Stomach 2-5 cm WT Intermedio 
36 M 60 Localized Small-bowel 2-5 cm  High 
37 M 46 Localized Stomach 5-10 cm c-kit 11 High 
38 F 60 Metastatic Unknown  c-kit 11  
39 M 75 Localized Rectus >10 cm c-kit 11 High 
40 M 34 Localized Small-bowel 2-5 cm  
                     
low 
41 F 79 Localized Stomach 2-5 cm  Intermedio 
42 F 69 Localized Stomach >10 cm  Low 
43 F 64 Localized Stomach 5-10 cm  High 
44 F 50 Localized Unknown >10 cm WT High 
45 M 67 Localized Stomach 2-5 cm  
                 very 
low 
46 F 33 Localized Stomach >10 cm c-kit 11 High 
47 M 48 Metastatic Unknown    
48 M 75 Metastatic Small-bowel  c-kit 11  
49 F 68 Localized Small-bowel >10 cm c-kit 9 High 
50 F 53 Localized Small-bowel 5-10 cm c-kit 11 Intermedio 
51 F 36 Localized Small-bowel  
PDGFRα 
18 High 
52 F 48 Localized Small-bowel 2-5 cm 
PDGFRα 
18 Low 
53 F 62 Localized Stomach 5-10 cm c-kit 11 High 
54 M 71 Localized Stomach 5-10 cm c-kit 11 Intermedio 
55 M 78 Localized Stomach 5-10 cm c-kit 11 Intermedio 
56 M 67 Localized Small-bowel 2-5 cm  Low 
57 F 56 Localized Small-bowel >10 cm c-kit 11 
                     
High 
58 M 46 Localized Small-bowel 2-5 cm c-kit 11 Low 
59 F 37 Localized Small-bowel 2-5 cm WT Low 
60 F 48 Localized Small-bowel 5-10 cm  Intermedio 
61 M 63 Localized Stomach >10 cm c-kit 11 Intermedio 
62 M 65 Localized Stomach 5-10 cm c-kit 11 High 
63 F 76 Localized Stomach 5-10 cm c-kit 11 High 
64 M 30 Localized Peritoneo 5-10 cm c-kit 9 High 
65 M 33 Localized Peritoneo 5-10 cm c-kit 11  
66 F 48 Localized Stomach 2-5 cm  Low 
67 F 50 Localized Stomach <2 cm 
PDGFRα 
12 very low 
68 M 71 Localized Small-bowel 2-5 cm  Low 
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RESULTS 
Today our center follows 80 patients, 39 women and 41 men, diagnosed 
between 2000 and 2010. The onset age was 55 years, with the following 
distribution by decades: 
 
0
5
10
15
20
25
21-30 31-40 41-50 51-60 61-70 71-80 81-90
Onset Age
Onset Age
 
 
The incidence by location agreed with literature’s reports and was distributed 
as follows: 
 
69 F 44 Localized Small-bowel >10 cm c-kit 9 High 
70 F 41 Metastatic Stomach >10 cm  High 
71 M 54 Localized Tenue 2-5 cm c-kit 9 Low 
72 F 65 Localized Small-bowel 2-5 cm  Low 
73 F 59 Localized Stomach >10 cm c-kit 11 High 
74 F 41 Localized Small-bowel 2-5 cm c-kit 9 Low 
75 M 80 Localized Stomach 5-10 cm c-kit 11 High 
76 F 52 Localized Stomach 5-10 cm c-kit 11 High 
77 F 54 Localized Stomach >10 cm  High  
78 M  80 Localized Rectum 5-10 cm  High 
79 F 67 Localized Stomach 2-5 cm  Intermedio 
80 M 70 Localized Stomach 2-5 cm  Intermedio 
17 
 
 
Primary Site
Esophagus
Unknown
Peritoneum
Rectum
Stomach
Small bowel
 
 
Patients 7 and 59 had a beginning leiomyoma diagnosis, patient 8 a 
fibrosarcoma diagnosis, patient 51 a liposarcoma, patient 63 a gastric 
carcinoma. 
The 54 cases analyzed by primary genetic mutations had a frequency resulting 
as follows: 
 
 
 
Patients with localized disease diagnosis were subjected to primitive tumor 
resection, except for patient 30 and 78 who are refusing the operation and are 
being treated with Imatinib 400mg/day. In 12 patients (13, 15, 16, 21, 31, 33, 
36, 47,66,75,77,79) it was not possible to realize a radical surgery (R1). In 
patients treated for resectable GIST the risk distribution by Fletcher was the 
following:  
 
 
In patients treated for resectable GIST the risk distribution by Miettinem was 
the following:  
 
Stratification of Risk of Relapse and metastasis (NCCN) Patients 
High 29 
Moderate 20 
Low 20 
Very low 3 
Total 72 
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Stratification of Risk of Relapse and metastasis (Miettinen) Patients 
High 28 
Moderate 13 
Low 23 
Very low 8 
Total 72 
 
Among the patients that went through surgery for localized GIST, 14 started an 
adjuvant treatment with Imatinib 400mg/day (among these, patients 16, 23, 33 
with average risk and patients 4, 6, 43, 46, 53,64,70,77,78,79 high risk). Patients 
23, 43, 46, 53 take Glivec as they have been included in EORTC 62024 study.  
The patients taking Glivec as adjuvant appear relapse-free in follow-up controls, 
except patient 70 that developed epatic and peritoneal metastasis. 
Patients 30 and 78, who had a potentially resectable GIST diagnosed, refuse 
surgery and therefore take Imatinib 400mg/die. 
Relapse patients, identified during follow-up controls, were 20 with the 
following risk distribution:  
 
Risk class Relapsed Patients 
High 14 
Moderate 4 
Low 2 
 Very Low 0 
 
 
In particular, 13 of the 20 relapse patients showed c-KIT in exon 11 mutation, 
two patients had c-KIT in exon 9 mutation, one patient had PDGFRα mutation, 
two patients had Wild Type for both genes. It is interesting to point out that 
low/average risk relapse patients carried mutation of c-KIT in exon 11 for 
deletion. This data cannot be considered statistically significant because of the 
poor sample number, nevertheless it is suggestive and confirms literature data 
reporting the mutation for delection in exon 11 of c-KIT as index of relatively 
malicious behavior of the primitive tumor (Andersson, Bumming, & Meis-
Kindblom, 2006). 
Considered T0 the time of the diagnosis in patients diagnosed for localized GIST 
with at least a five-year follow-up time non-stratified for risk Relapse Free 
Survival (RFS) we obtain a 56-months mediane:  
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By stratifying RFS for risk under Fletcher we obtain:  
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This curve shows how RFS is related to the risk calculated upon dimensions and 
mitotic count, even if the poor sample number and the short follow-up period 
make the analysis not significant. The RFS mediane in high risk patients was 31 
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months, while the mediane in low/average risk was not reached within the five 
follow-up years.  
By analysing the RFS curve under Miettinen’s risk stratification we obtain: 
 
 
A significant analysis is obtained. Miettinen’s risk stratification proves to have a 
better predictive value than NIH/Fletcher.   
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As it is expected by Miettinen’s risk stratification, 10/16 relapsed patients had a 
primary disease localized at the small intestine, which is confirmed to be the 
highest relapse-risk location (Miettinen & Lasota, 2006). 
Patient 7 was operated for relapse excision and is today treated with Imatinib 
400mg/day, disease-free. 
Patient 61 was treated at relapse with Imatinib 400mg/die with neo-adjuvant 
purpose for a big relapse located in the pelvic area, which was removed after six 
months of treatment. The patient keeps taking Imatinib 400mg/day, disease-
free. 
Patients 1, 11, 44, 49, 50, 51, 62 with disease relapse and patients 12, 13, 21, 
31, 47, 48 with metastatic disease at diagnosis were treated with debulking 
surgery and then with Imatinib 400mg/day. The other patients with inoperable 
relapsed or metastatic disease have been treated with Imatinib 400mg/day. 
To date we have been treating 28 patients with Imatinib 400mg/day for 
metastatic or relapsed disease. 11/28 patients carry on their Imatinib 
400mg/day treatment. Three-years PFS, calculated on 19 patients having a 36 
months since the beginning of the treatment follow-up, shows a 27 months 
mediane: 
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It is interesting to point out that patients with disease progression after a few 
months of treatment were not carrying exon 11 mutation. 
No relevant toxicity occurred during the Imatinib treatment with standard 
dosage. The most common collateral effect was, as it is expected to be, 
periorbital edema. Dosage reduction or cure interruption, have never been 
necessary.  
Progressing patients with Imatinib 400mg/day (15) have then received Imatinib 
800mg/day except for patient 51 who received a protein kinases C inhibitor, 
and patient 63 who received Sunitinib. The increase of Imatinib dosage proved 
to be useful since it delayed the progression of the disease even in patients 
carrying mutations that were different from those in exon 11. PFS under 
Kaplan-Meier, calculated on patients having a treatment follow-up since at least 
a year (15) shows a nine months mediane:  
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The tolerance of the treatment is lower than the standard dose, the most 
common collateral effects have been periorbital edema, hematologic 
alterations. 
In progressing patients with Imatinib 800mg/day (12) the treatment with 
Sunitinib 37,5mg/day (Sutent) started – a treatment that was recorded for 
progressing metastatic GIST or Imatinib patients. Today Sunitinib is daily taken. 
Patient 47 was taking Sunitinib under 4+2 schedule, which, even though more 
tolerated, did not prove to be advantageous in GIST for the effect of interval 
progression. 
Sunitinib has significantly shown, despite its lower tolerability against Imatinib, 
to extend PFS. Last studies seem to suggest that it is more effective in patients 
carrying mutation of c-KIT in exon 9. The data we acquired on two patients 
carrying exon 9 mutation actually prove that the response in terms of PFS has 
been superior to Sunitinib in second line, rather than to Imatinib 400mg/day in 
first line. 
PFS in patients being treated with Sunitinib since at least six months was the 
following: 
 
Most common collateral effects were thrombocytopenia, hematologic 
alterations, mucositis, hand-foot syndrome. The temporary suspension of the 
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treatment was necessary in one patient because of toxicity. The dosage 
reduction was not followed by clinic improvements. Patients 1 and 62 
interrupted the treatment for two months for surgical operation (for other 
causes). 
At the moment there is no indication about a third-line treatment. Patients 
progressing during Sunintinb treatment have the chance to be enlisted in a 
clinic trial or the Imatinib rechallenging. Our center acquired experience with 
protein kinases C inhibitors, with Nilotinib (a new-generation TK inhibitor) and 
Imatinib in re-challenging. 
Seven patients have been treated with Nilotinib 800mg/day, which proved a 
remarkable anti-tumoral activity and a high tolerability, and recently showed a 
better efficiency than Imantinib in treating Chronic Myeloid Leukemia and is in 
trial against Imatinib for the first-line metastatic GIST treatment. However, the 
medicine did not prove the expected third-line efficiency and does not seem to 
bring OS improvements. During our experience, thanks to a compassionate 
utilization program, we obtained partial short-lasting responses, followed by a 
SUV reduction in PET investigation. The PFS after seven months showed a three-
months mediane: 
 
 
Picture 40 Metastatic GIST in response to third-line Nilotinib treatment 
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The rechallenging with Imatinib, by our experience (counting only three 
patients) seems to have only a palliative role, that can decelerate the disease 
progression. 
 
DISCUSSION  
The data we obtained are in line with the literature data concerning the average 
starting age, the location and the frequency of mutations. RFS data show that 
Miettinen’s risk stratification has a better discriminative capacity (p<0,05) 
between patients at higher and lower relapse risk against NIH/Fletcher 
stratification. Moreover, the data about the relapse onset, which occurred for 
primitive tumors in small intestine in 10/16 cases, confirm that the location 
parameter is an important prognostic factor, inseparable from the dimension 
and the mitotic count of the primitive tumor. 
Patients that went through R1 surgery for localized GIST did not show a 
significant relapse increment after three years against patients treated with R0 
surgery. 
Neo-adjuvant treatment with Imatinib 400mg/day can increase the chances of 
an R0 surgery and should always be considered as an alternative option to 
primary surgery for big tumors. 
Our data about the efficacy of the adjuvant therapy confirm its importance in 
increasing the chances of relapse-free survival. 
Patients with a single-location non-metastatic relapse can benefit from a new 
surgical treatment and following Imatinib 400mg/day therapy.  
Tyrosine kinase inhibitors treatment is to be chosen for metastatic or relapsed 
with metastasis patients, except for some strictly selected cases in which 
surgery can actually represent a recovery chance (e.g. single-location relapse). 
In these cases an Imatinib neo-adjuvant treatment is proved to be useful, 
followed within 6 and 12 months by relapse resection.  
The preliminary data about the mutational analysis realized on relapsed 
patients show a predominance of exon 11 alterations that, even though this 
mutational pattern ensures today the best response to the target Imatinib 
therapy in metastatic setting, seems to be a negative prognostic factor in terms 
of relapse. For this reason, the genetic analysis should be a standard of the 
diagnostic-staging iter of the patient with localized and resectable GIST, as well 
as of the metastatic patient as the guidelines say, as it is able to provide another 
prognostic parameter of the relapse risk and of the efficiency evaluation of an 
adjuvant treatment.  
 
CONCLUSIONS 
In conclusion, since KIT and PDGFRα mutations have therapeutic and prognostic 
roles, GIST genotyping should be considered as a standard clinic test both for 
resected, relapse-risk or metastatic tumors, in order to provide an eventual 
adjuvant treatment, for prognostic evaluation in metastases setting and to 
exclude the resistant GISTs. The subsequent data about this subject, together 
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with the increasing availability of target therapies will enable, in the future, 
individualized therapy – in order to achieve the best benefit for the patient.  
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